World Health Organization. Chronic obstructive pulmonary disease (COPD) 2023 Available from: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd.
Ruvuna L, Sood A. Epidemiology of chronic obstructive pulmonary disease. Clin Chest Med. 2020;41(3):315–27.
Venkatesan P. GOLD report: 2022 update. Lancet Respir Med. 2022;10(2):1–12.
Hanlon P, Nicholl BI, Jani BD, McQueenie R, Lee D, Gallacher KI, et al. Examining patterns of multimorbidity, polypharmacy and risk of adverse drug reactions in chronic obstructive pulmonary disease: a cross-sectional UK Biobank study. BMJ Open. 2018;8(1):1–17.
Divo M, Celli BR. Multimorbidity in patients with chronic obstructive pulmonary disease. Clin Chest Med. 2020;41(3):405–19.
Valderas JM, Starfield B, Sibbald B, Salisbury C, Roland M. Defining comorbidity: implications for understanding health and health services. Ann Fam Med. 2009;7(4):357–63.
Lee AL, Goldstein RS. Gastroesophageal reflux disease in COPD: links and risks. Int J Chron Obstruct Pulmon Dis. 2015;1(1):1935–49.
Vanfleteren L, Spruit MA, Wouters EFM, Franssen FME. Management of chronic obstructive pulmonary disease beyond the lungs. Lancet Respir Med. 2016;4(11):911–24.
Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11(1):1–13.
Panagioti M, Scott C, Blakemore A, Coventry PA. Overview of the prevalence, impact, and management of depression and anxiety in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2014;5(3):1289–306.
Rabe KF, Hurst JR, Suissa S. Cardiovascular disease and COPD: dangerous liaisons? Eur Respir Rev. 2018;27(149):1–17.
Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(8):631–9.
Rennard SI, Locantore N, Delafont B, Tal-Singer R, Silverman EK, Vestbo J, et al. Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis. Ann Am Thorac Soc. 2015;12(3):303–12.
Putcha N, Drummond MB, Wise RA, Hansel NN. Comorbidities and chronic obstructive pulmonary disease: prevalence, influence on outcomes, and management. Semin Respir Crit Care Med. 2015;36(4):575–91.
Mirza S, Clay RD, Koslow MA, Scanlon PD. COPD guidelines: a review of the 2018 GOLD report. Mayo Clin Proc. 2018;93(10):1488–502.
Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5):1–15.
Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):1–23.
Miravitlles M, Ferrer M, Pont A, Zalacain R, Alvarez-Sala JL, Masa F, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax. 2004;59(5):387–95.
Stöber A, Lutter JI, Schwarzkopf L, Kirsch F, Schramm A, Vogelmeier CF, et al. Impact of lung function and exacerbations on health-related quality of life in COPD patients within one year: real-world analysis based on claims data. Int J Chron Obstruct Pulmon Dis. 2021;16(1):2637–51.
Berry CE, Wise RA. Mortality in COPD: causes, risk factors, and prevention. COPD. 2010;7(5):375–82.
Alqahtani JS. Prevalence, incidence, morbidity and mortality rates of COPD in Saudi Arabia: rends in burden of COPD from 1990 to 2019. PLoS ONE. 2022;17(5):1–12.
Hospital MoHANS. Al Noor Specialist Hospital. 2023. Available from: http://nsh.med.sa/Pages/AboutUs.aspx#.
Naser AY, Dairi MS, Alwafi H, Ashoor DS, Qadus S, Aldhahir AM, et al. The rate of ward to intensive care transfer and its predictors among hospitalized COPD patients, a retrospective study in a local tertiary center in Saudi Arabia. BMC Pulm Med. 2023;23(1):1–14.
Varghese D IC, Haseer Koya H. Polypharmacy. Treasure Island (FL). 2023. Available from: https://pubmed.ncbi.nlm.nih.gov/30422548/.
Anne D, Halli-Tierney CS, Carroll D. Polypharmacy: evaluating risks and deprescribing. Am Fam Physician. 2019;1(100):1–11.
Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):1–23.
Echave-Sustaeta JM, Comeche Casanova L, Cosio BG, Soler-Cataluña JJ, Garcia-Lujan R, Ribera X. Comorbidity in chronic obstructive pulmonary disease. Related to disease severity. Int J Chron Obstruct Pulmon Dis. 2014;1(1):1307–14.
Díez-Manglano J, Barquero-Romero J, Mena PA, Recio-Iglesias J, Cabrera-Aguilar J, López-García F, et al. Polypharmacy in patients hospitalised for acute exacerbation of COPD. Eur Respir J. 2014;44(3):791–4.
Chetty U, McLean G, Morrison D, Agur K, Guthrie B, Mercer SW. Chronic obstructive pulmonary disease and comorbidities: a large cross-sectional study in primary care. Br J Gen Pract. 2017;67(658):321–8.
Koper D, Kamenski G, Flamm M, Böhmdorfer B, Sönnichsen A. Frequency of medication errors in primary care patients with polypharmacy. Fam Pract. 2013;30(3):313–9.
Basques BA, Bohl DD, Golinvaux NS, Leslie MP, Baumgaertner MR, Grauer JN. Postoperative length of stay and 30-day readmission after geriatric hip fracture: an analysis of 8434 patients. J Orthop Trauma. 2015;29(3):115.
Basques BA, Varthi AG, Golinvaux NS, Bohl DD, Grauer JN. Patient characteristics associated with increased postoperative length of stay and readmission after elective laminectomy for lumbar spinal stenosis. Spine. 2014;39(10):1–18.
Pugely AJ, Callaghan JJ, Martin CT, Cram P, Gao Y. Incidence of and risk factors for 30-day readmission following elective primary total joint arthroplasty: analysis from the ACS-NSQIP. J Arthroplasty. 2013;28(9):1499–504.
Clement RC, Derman PB, Graham DS, Speck RM, Flynn DN, Levin LS, et al. Risk factors, causes, and the economic implications of unplanned readmissions following total hip arthroplasty. J Arthroplasty. 2013;28(8):7–10.
Paxton EW, Inacio MC, Singh JA, Love R, Bini SA, Namba RS. Are there modifiable risk factors for hospital readmission after total hip arthroplasty in a US healthcare system? Clin Orthop Related Res®. 2015;4731(1):3446–55.
Zhang JQ, Curran T, McCallum JC, Wang L, Wyers MC, Hamdan AD, et al. Risk factors for readmission after lower extremity bypass in the American College of Surgeons National Surgery Quality Improvement Program. J Vasc Surg. 2014;59(5):1331–9.
Hannan EL, Zhong Y, Lahey SJ, Culliford AT, Gold JP, Smith CR, et al. 30-day readmissions after coronary artery bypass graft surgery in New York State. JACC. 2011;4(5):569–76.
Basques BA, Gardner EC, Varthi AG, Fu MC, Bohl DD, Golinvaux NS, et al. Risk factors for short-term adverse events and readmission after arthroscopic meniscectomy: does age matter? Am J Sports Med. 2015;43(1):169–75.
Lovecchio F, Farmer R, Souza J, Khavanin N, Dumanian GA, Kim JY. Risk factors for 30-day readmission in patients undergoing ventral hernia repair. Surgery. 2014;155(4):702–10.
Catanzarite T, Vieira B, Qin C, Milad MP. Risk factors for unscheduled 30-day readmission after benign hysterectomy. South Med J. 2015;108(9):524–30.
Jennings DL, Petricca JC, Yageman LA, O’Dell K, Kalus JS. Predictors of rehospitalization after acute coronary syndromes. Am J Health Syst Pharm. 2006;63(4):367–72.
El Solh AA, Brewer T, Okada M, Bashir O, Gough M. Indicators of recurrent hospitalization for pneumonia in the elderly. J Am Geriatr Soc. 2004;52(12):2010–5.
Wehling M. Multimorbidity and polypharmacy: how to reduce the harmful drug load and yet add needed drugs in the elderly? Proposal of a new drug classification: fit for the aged. J Am Geriatr Soc. 2009;57(3):560–1.
Teljeur C, Smith SM, Paul G, Kelly A, O’Dowd T. Multimorbidity in a cohort of patients with type 2 diabetes. Eur J Gen Pract. 2013;19(1):17–22.
Corsonello A, Pedone C, Corica F, Incalzi RA. Polypharmacy in elderly patients at discharge from the acute care hospital. Ther Clin Risk Manag. 2007;3(1):197–203.
Miravitlles M, Ribera A. Understanding the impact of symptoms on the burden of COPD. Respir Res. 2017;18(1):1–11.
Miller J, Edwards L, Agustí A, Bakke P, Calverley P, Celli B, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med. 2013;107(9):1376–84.
Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296–310.
Trotta MP, Ammassari A, Melzi S, Zaccarelli M, Ladisa N, Sighinolfi L, et al. Treatment-related factors and highly active antiretroviral therapy adherence. JAIDS Acquir Immune Defic Syndr. 2002;31(1):S128–31.
Franssen FM, Spruit MA, Wouters EF. Determinants of polypharmacy and compliance with GOLD guidelines in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2011;1(1):493–501.
Willson MN, Greer CL, Weeks DL. Medication regimen complexity and hospital readmission for an adverse drug event. Ann Pharmacother. 2014;48(1):26–32.
Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010. BMC Med. 2015;13(1):1–10.
Bourgeois FT, Shannon MW, Valim C, Mandl KD. Adverse drug events in the outpatient setting: an 11-year national analysis. Pharmacoepidemiol Drug Saf. 2010;19(9):901–10.
Johnell K, Klarin I. The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600 000 elderly patients from the Swedish prescribed drug register. Drug Saf. 2007;30(1):911–8.
Bayliss EA, Edwards AE, Steiner JF, Main DS. Processes of care desired by elderly patients with multimorbidities. Fam Pract. 2008;25(4):287–93.
Veehof L, Stewart R, Meyboom-de Jong B, Haaijer-Ruskamp F. Adverse drug reactions and polypharmacy in the elderly in general practice. Eur J Clin Pharmacol. 1999;55(1):533–6.
Kadam UT. Potential health impacts of multiple drug prescribing for older people: a case-control study. Br J Gen Pract. 2011;61(583):128–30.
Negewo NA, Gibson PG, Wark PA, Simpson JL, McDonald VM. Treatment burden, clinical outcomes, and comorbidities in COPD: an examination of the utility of medication regimen complexity index in COPD. Int J Chron Obstruct Pulmon Dis. 2017;1(1):2929–42.
Yeh A, Shah-Manek B, Lor KB. Medication regimen complexity and A1C goal attainment in underserved adults with type 2 diabetes: a cross-sectional study. Ann Pharmacother. 2017;51(2):111–7.
Johnson J, Booman L. Drug-related morbidity and mortality. J Manag Care Pharm. 1996;2(1):39–47.
Boyd CM, Fortin M. Future of multimorbidity research: how should understanding of multimorbidity inform health system design? Public Health Rev. 2010;32(2):451–74.
Loza E, Jover JA, Rodriguez L, Carmona L, Group ES, editors. Multimorbidity: prevalence, effect on quality of life and daily functioning, and variation of this effect when one condition is a rheumatic disease. Seminars in arthritis and rheumatism; 2009: Elsevier.
Add Comment